ArticlePloS one2025
PLA2R1 and HLA-DQA1 SNP in patients with primary membranous nephropathy.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary membranous nephropathy is a widely recognized autoimmune disease associated with podocyte antigens; the most important autoantigen is PLA2R1. PLA2R1 and HLA-DQA1 play important roles in the production of pathogenic antibodies. The purpose of this study was to observe the relationship between gene polymorphisms and primary membranous nephropathy and explore the clinical functional clues of PLA2R1 and HLA-DQA1 genes affecting treatment responsiveness.
methodThe study enrolled 89 patients with primary membranous nephropathy and 91 healthy people as a control. Single-nucleotide polymorphism loci (seven on PLA2R1 and two on HLA-DQA1) were identified using the PCR-Sanger technique. The patients were followed up until the 12th month, and relevant clinical data were collected. The relationship between these single-nucleotide polymorphism loci and primary membranous nephropathy remission was analyzed.
resultGenotypic and allelic frequency distributions for six single-nucleotide polymorphisms within PLA2R1 (rs4664308, rs3792189, rs3792192, rs1870102, rs17831251, and rs35771982) and one in HLA-DQA1 (rs2187668) were associated with morbidity of primary membranous nephropathy. Single-nucleotide polymorphisms rs1870102, rs17831251, and rs2187668 were statistically significant in the genetic model analysis. The odds ratio for primary membranous nephropathy in patients carrying rs2187668 GG and rs1870102 AA was 52.875. We found that PLA2R1 single-nucleotide polymorphism rs36771982 was related to proteinuria remission at the 12th month, and found in further analysis that PLA2R1 single-nucleotide polymorphisms rs3792189, rs3792192, rs17831251, and rs35771982 were related to treatment response in the RTX group.
conclusionIn this study, we found several PLA2R1 and HLA-DQA1 single-nucleotide polymorphism loci associated with primary membranous nephropathy morbidity and that some PLA2R1 single-nucleotide polymorphism loci were related to the treatment response of patients with primary membranous nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.